NCT02406521View on ClinicalTrials.gov

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2019

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

Pazopanib

DRUG

Sorafenib

DRUG

Radium-223

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02406521 - Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets | Biotech Hunter | Biotech Hunter